# Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors

> **NCT00039494** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 171 (estimated)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma

## Interventions

- **DRUG:** erlotinib hydrochloride
- **RADIATION:** 3-dimensional conformal radiation therapy
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00039494
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 171 (ESTIMATED)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039494, "Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00039494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*